Literature DB >> 32960290

Comparative studies of urolithins and their phase II metabolites on macrophage and neutrophil functions.

Aneta Bobowska1, Sebastian Granica1, Agnieszka Filipek1, Matthias F Melzig2, Thomas Moeslinger3, Jürgen Zentek4, Aleksandra Kruk1, Jakub P Piwowarski5,6,7.   

Abstract

PURPOSE: Ellagitannins are high molecular weight polyphenols present in high quantities in various food products. They are metabolized by human and animal gut microbiota to postbiotic metabolites-urolithins, bioavailable molecules of a low molecular weight. Following absorption in the gut, urolithins rapidly undergo phase II metabolism. Thus, to fully evaluate the mechanisms of their biological activity, the in vitro studies should be conducted for their phase II conjugates, mainly glucuronides. The aim of the study was to comparatively determine the influence of urolithin A, iso-urolithin A, and urolithin B together with their respective glucuronides on processes associated with the inflammatory response.
METHODS: The urolithins obtained by chemical synthesis or isolation from microbiota cultures were tested with their respective glucuronides isolated from human urine towards modulation of inflammatory response in THP-1-derived macrophages, RAW 264.7 macrophages, PBMCs-derived macrophages, and primary neutrophils.
RESULTS: Urolithin A was confirmed to be the most active metabolite in terms of LPS-induced inflammatory response inhibition (TNF-α attenuation, IL-10 induction). The observed strong induction of ERK1/2 phosphorylation has been postulated as the mechanism of its action. None of the tested glucuronide conjugates was active in terms of pro-inflammatory TNF-α inhibition and anti-inflammatory IL-10 and TGF-β1 induction.
CONCLUSION: Comparative studies of the most abundant urolithins and their phase II conjugates conducted on human and murine immune cells unambiguously confirmed urolithin A to be the most active metabolite in terms of inhibition of the inflammatory response. Phase II metabolism was shown to result in the loss of urolithins' pharmacological properties.

Entities:  

Keywords:  Ellagitannins; Inflammation; Phase II metabolism; Postbiotics; Urolithins

Year:  2020        PMID: 32960290     DOI: 10.1007/s00394-020-02386-y

Source DB:  PubMed          Journal:  Eur J Nutr        ISSN: 1436-6207            Impact factor:   5.614


  40 in total

1.  Ellagitannin metabolites, urolithin A glucuronide and its aglycone urolithin A, ameliorate TNF-α-induced inflammation and associated molecular markers in human aortic endothelial cells.

Authors:  Juan A Giménez-Bastida; Antonio González-Sarrías; Mar Larrosa; Francisco Tomás-Barberán; Juan C Espín; María-Teresa García-Conesa
Journal:  Mol Nutr Food Res       Date:  2012-05       Impact factor: 5.914

2.  Differences in Metabolism of Ellagitannins by Human Gut Microbiota ex Vivo Cultures.

Authors:  Jakub P Piwowarski; Sebastian Granica; Joanna Stefańska; Anna K Kiss
Journal:  J Nat Prod       Date:  2016-11-23       Impact factor: 4.050

Review 3.  Polyphenol supplementation as a complementary medicinal approach to treating inflammatory bowel disease.

Authors:  F Biasi; M Astegiano; M Maina; G Leonarduzzi; G Poli
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

4.  Ellagitannins, ellagic acid and vascular health.

Authors:  Mar Larrosa; María T García-Conesa; Juan C Espín; Francisco A Tomás-Barberán
Journal:  Mol Aspects Med       Date:  2010-09-15

5.  In vivo anti-inflammatory and antioxidant properties of ellagitannin metabolite urolithin A.

Authors:  Hidekazu Ishimoto; Mari Shibata; Yuki Myojin; Hideyuki Ito; Yukio Sugimoto; Akihiro Tai; Tsutomu Hatano
Journal:  Bioorg Med Chem Lett       Date:  2011-07-29       Impact factor: 2.823

Review 6.  Metabolic fate of ellagitannins: implications for health, and research perspectives for innovative functional foods.

Authors:  Cristina Garcia-Muñoz; Fabrice Vaillant
Journal:  Crit Rev Food Sci Nutr       Date:  2014       Impact factor: 11.176

7.  Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism.

Authors:  Mar Larrosa; Antonio González-Sarrías; María J Yáñez-Gascón; María V Selma; María Azorín-Ortuño; Simona Toti; Francisco Tomás-Barberán; Piero Dolara; Juan Carlos Espín
Journal:  J Nutr Biochem       Date:  2009-07-18       Impact factor: 6.048

8.  Tormentil for active ulcerative colitis: an open-label, dose-escalating study.

Authors:  Roman Huber; Amelie V Ditfurth; Frank Amann; Corina Güthlin; Matthias Rostock; Rainer Trittler; Klaus Kümmerer; Irmgard Merfort
Journal:  J Clin Gastroenterol       Date:  2007-10       Impact factor: 3.062

9.  Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts.

Authors:  Ramón Estruch; Emilio Ros; Jordi Salas-Salvadó; Maria-Isabel Covas; Dolores Corella; Fernando Arós; Enrique Gómez-Gracia; Valentina Ruiz-Gutiérrez; Miquel Fiol; José Lapetra; Rosa M Lamuela-Raventos; Lluís Serra-Majem; Xavier Pintó; Josep Basora; Miguel A Muñoz; José V Sorlí; J Alfredo Martínez; Montserrat Fitó; Alfredo Gea; Miguel A Hernán; Miguel A Martínez-González
Journal:  N Engl J Med       Date:  2018-06-13       Impact factor: 91.245

10.  Urolithin A attenuates pro-inflammatory mediator production by suppressing PI3-K/Akt/NF-κB and JNK/AP-1 signaling pathways in lipopolysaccharide-stimulated RAW264 macrophages: Possible involvement of NADPH oxidase-derived reactive oxygen species.

Authors:  Wataru Komatsu; Hisashi Kishi; Kazumi Yagasaki; Shuji Ohhira
Journal:  Eur J Pharmacol       Date:  2018-06-20       Impact factor: 4.432

View more
  8 in total

1.  Conjugates of urolithin A with NSAIDs, their stability, cytotoxicity, and anti-inflammatory potential.

Authors:  Maciej Korczak; Piotr Roszkowski; Sebastian Granica; Jakub P Piwowarski
Journal:  Sci Rep       Date:  2022-07-08       Impact factor: 4.996

2.  Preclinical Evaluation of Oral Urolithin-A for the Treatment of Acute Campylobacteriosis in Campylobacter jejuni Infected Microbiota-Depleted IL-10-/- Mice.

Authors:  Soraya Mousavi; Dennis Weschka; Stefan Bereswill; Markus M Heimesaat
Journal:  Pathogens       Date:  2020-12-23

Review 3.  Therapeutic Potential of Mitophagy-Inducing Microflora Metabolite, Urolithin A for Alzheimer's Disease.

Authors:  Dona Pamoda W Jayatunga; Eugene Hone; Harjot Khaira; Taciana Lunelli; Harjinder Singh; Gilles J Guillemin; Binosha Fernando; Manohar L Garg; Giuseppe Verdile; Ralph N Martins
Journal:  Nutrients       Date:  2021-10-23       Impact factor: 5.717

Review 4.  Urolithins: The Colon Microbiota Metabolites as Endocrine Modulators: Prospects and Perspectives.

Authors:  Ravindran Vini; Juberiya M Azeez; Viji Remadevi; T R Susmi; R S Ayswarya; Anjana Sasikumar Sujatha; Parvathy Muraleedharan; Lakshmi Mohan Lathika; Sreeja Sreeharshan
Journal:  Front Nutr       Date:  2022-02-02

5.  Urolithins Modulate the Viability, Autophagy, Apoptosis, and Nephrin Turnover in Podocytes Exposed to High Glucose.

Authors:  Milena Kotewicz; Mirosława Krauze-Baranowska; Agnieszka Daca; Agata Płoska; Sylwia Godlewska; Leszek Kalinowski; Barbara Lewko
Journal:  Cells       Date:  2022-08-09       Impact factor: 7.666

6.  Urolithin B suppressed osteoclast activation and reduced bone loss of osteoporosis via inhibiting ERK/NF-κB pathway.

Authors:  Yajun Li; Qi Zhuang; Lihong Tao; Kai Zheng; Shuangshuang Chen; Yunshang Yang; Chengcheng Feng; Zhifang Wang; Haiwei Shi; Jiandong Shi; Yiling Fang; Long Xiao; Dechun Geng; Zhirong Wang
Journal:  Cell Prolif       Date:  2022-06-16       Impact factor: 8.755

Review 7.  Potential Modulatory Microbiome Therapies for Prevention or Treatment of Inflammatory Bowel Diseases.

Authors:  Daan V Bunt; Adriaan J Minnaard; Sahar El Aidy
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-26

Review 8.  Urolithins: Diet-Derived Bioavailable Metabolites to Tackle Diabetes.

Authors:  Ana F Raimundo; Sofia Ferreira; Francisco A Tomás-Barberán; Claudia N Santos; Regina Menezes
Journal:  Nutrients       Date:  2021-11-27       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.